Skip to main content
. Author manuscript; available in PMC: 2020 Oct 17.
Published in final edited form as: Sci Transl Med. 2019 Aug 7;11(504):eaau4972. doi: 10.1126/scitranslmed.aau4972

Fig. 7. Pyrimidine metabolism informs poor clinical outcome in glioblastoma.

Fig. 7.

(A and B) KEGG pyrimidine metabolism signature ssGSEA score distribution between nontumor and tumor specimens in TCGA glioblastoma (GBM) HG-U133A (A) and among different grades in TCGA glioblastoma-LGG RNA-seq V2 datasets (B). (C) mRNA expression pattern of genes comprising the KEGG pyrimidine metabolism signature and corresponding ssGSEA score distribution in TCGA glioblastoma-LGG cohort (n = 667) stratified by TCGA DNA methylation cluster groups and associated molecular markers. G-CIMP, glioma CpG island methylator phenotype. (D to I) Kaplan-Meier survival analysis based on KEGG pyrimidine metabolism signature ssGSEA scores stratified by the median of six different glioma datasets: (D) TCGA glioblastoma (34), (E) TCGA glioblastoma-LGG RNA-seq (35), (F) REMBRANDT (36), (G) Gravendeel (37), (H) Phillips (38), and (I) Freije (39).